Group One Trading, L.P. Ovid Therapeutics Inc. Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$1.85 - $2.26 $66 - $81	-36 Reduced 2.3%	1,532 $3,000
Q2 2022 Aug 11, 2022	SELL	$1.69 - $3.31 $2,535 - $4,965	-1,500 Reduced 48.89%	1,568 $3,000
Q1 2022 May 12, 2022	SELL	$2.65 - $3.49 $26,070 - $34,334	-9,838 Reduced 76.23%	3,068 $10,000
Q4 2021 Feb 11, 2022	SELL	$3.13 - $3.73 $129,585 - $154,425	-41,401 Reduced 76.24%	12,906 $41,000
Q3 2021 Nov 12, 2021	SELL	$3.31 - $4.04 $37,714 - $46,031	-11,394 Reduced 17.34%	54,307 $182,000

Q2 2021 Aug 10, 2021	SELL	$3.3 - $4.49 $332,161 - $451,940	-100,655 Reduced 60.51%	65,701 $257,000
Q1 2021 May 12, 2021	BUY	$2.42 - $4.47 $243,744 - $450,222	100,721 Added 153.46%	166,356 $669,000
Q4 2020 Feb 10, 2021	BUY	$2.28 - $6.84 $149,506 - $448,519	65,573 Added 105762.9%	65,635 $152,000
Q3 2020 Nov 12, 2020	SELL	$5.39 - $8.24 $44,941 - $68,705	-8,338 Reduced 99.26%	62 $0
Q2 2020 Aug 13, 2020	BUY	$2.67 - $7.91 $22,428 - $66,444	8,400 New	8,400 $62,000

43.2M

5.9K

300

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $52.8M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.